5-Aryl-furan derivatives bearing a phenylalanine- or isoleucine-derived rhodanine moiety as potential PTP1B inhibitors.

Authors :: Niu T
Wang P
Li C
Dou T
Piao H
Li J
Sun L
Source :: Bioorganic chemistry [Bioorg Chem] 2021 Jan; Vol. 106, pp. 104483. Date of Electronic Publication: 2020 Nov 19.
Publication Year :: 2021
Abstract: Two series of 5-aryl-furan derivatives bearing a phenylalanine- or isoleucine-derived rhodanine moiety were identified as competitive protein tyrosine phosphatase 1B (PTP1B) inhibitors. Among the compounds studied, 5g was found to have the best PTP1B inhibitory potency (IC <subscript>50</subscript>  = 2.66 ± 0.16 µM) and the best cell division cycle 25 homolog B (CDC25B) inhibitory potency (IC <subscript>50</subscript>  = 0.25 ± 0.02 µM). Enzymatic data together with molecular modeling results demonstrated that the introduction of a sec-butyl group at the 2-position of the carboxyl group remarkably improved the PTP1B inhibitory activity.<br /> (Copyright © 2020 Elsevier Inc. All rights reserved.)

Subjects :: Dose-Response Relationship, Drug
Enzyme Inhibitors chemical synthesis
Enzyme Inhibitors chemistry
Furans chemical synthesis
Furans chemistry
Humans
Isoleucine chemistry
Molecular Structure
Phenylalanine chemistry
Protein Tyrosine Phosphatase, Non-Receptor Type 1 metabolism
Rhodanine chemistry
Structure-Activity Relationship
Enzyme Inhibitors pharmacology
Furans pharmacology
Isoleucine pharmacology
Phenylalanine pharmacology
Protein Tyrosine Phosphatase, Non-Receptor Type 1 antagonists & inhibitors
Rhodanine pharmacology

Full Text Access

Tools